When does dulaglutide’s patent expire?
Dulaglutide (Trulicity) is protected by a set of patents covering different aspects of the drug, so “the” expiry date depends on which patent(s) you mean (drug substance/process, formulation, dosing regimen, and related protections). Patent expiry timing also differs by country and can be extended by patent term adjustments or regulatory-related extensions in some jurisdictions.
Which patents are most relevant for dulaglutide market exclusivity?
For brand drugs like dulaglutide, market protection usually involves multiple layers:
- Patent protection for the active ingredient and manufacturing or formulation.
- Additional patents around specific dosing, delivery device, or related claims.
- Regulatory exclusivities (where they apply) that can delay generic entry even after some patents end.
Because these protections do not all expire on the same date, the effective “generic start” date is often later than the earliest patent expiry.
Can generics or biosimilars enter right after the first patent expires?
Usually not immediately. Even if one patent expires, other patents can still block generic competition, and regulatory exclusivities may also apply. For dulaglutide specifically, entry timing will depend on which patent claims a generic or biosimilar challenges and whether it can launch without infringing any remaining in-force patents.
Does dulaglutide face patent challenges (and what do they change)?
When a challenger files a biosimilar/generic pathway, courts may determine whether specific patents are invalid or not infringed. Those legal outcomes can shift launch timing relative to the nominal patent expiry calendar, depending on injunctions, appeals, and settlement agreements.
Do international markets have different dulaglutide expiry dates?
Yes. Patent filings, term calculations, and extensions vary by country, so expiry dates and launch timelines can differ across the US, EU, UK, and other jurisdictions. If you tell me the country (or region) you care about, I can narrow the answer to the relevant legal timeframe.
If you want a single “expected” launch timeframe, what info do you need?
To translate “patent expiry” into a practical expectation for dulaglutide competition, you typically need:
- The country/region
- Whether you mean biosimilar vs. generic (dulaglutide is a biologic, so biosimilars are the usual pathway)
- Whether you care about earliest patent expiry or the point at which product entry becomes feasible despite remaining patents and exclusivities
Sources:
No sources were provided with the question, so I can’t cite specific dulaglutide patent expiry dates or case outcomes.